Spascupreel

Aconitum Napellus, Ammonium Bromide, Citrullus Colocynthis Fruit Pulp, Atropine Sulfate, Gelsemium Sempervirens Root, Magnesium Phosphate, Dibasic Trihydrate, Veratrum Album Root, Passiflora Incarnata Flowering Top, Matricaria Recutita, Amanita Muscaria Fruiting Body And Cupric Sulfate


Medinatura Inc
Human Prescription Drug
NDC 50114-7040
Spascupreel also known as Aconitum Napellus, Ammonium Bromide, Citrullus Colocynthis Fruit Pulp, Atropine Sulfate, Gelsemium Sempervirens Root, Magnesium Phosphate, Dibasic Trihydrate, Veratrum Album Root, Passiflora Incarnata Flowering Top, Matricaria Recutita, Amanita Muscaria Fruiting Body And Cupric Sulfate is a human prescription drug labeled by 'Medinatura Inc'. National Drug Code (NDC) number for Spascupreel is 50114-7040. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Spascupreel drug includes Aconitum Napellus - 6 [hp_X]/1.1mL Amanita Muscaria Fruiting Body - 4 [hp_X]/1.1mL Ammonium Bromide - 4 [hp_X]/1.1mL Atropine Sulfate - 6 [hp_X]/1.1mL Citrullus Colocynthis Fruit Pulp - 4 [hp_X]/1.1mL Cupric Sulfate - 6 [hp_X]/1.1mL Gelsemium Sempervirens Root - 6 [hp_X]/1.1mL Magnesium Phosphate, Dibasic Trihydrate - 6 [hp_X]/1.1mL Matricaria Recutita - 3 [hp_X]/1.1mL Passiflora Incarnata Flowering Top - 2 [hp_X]/1.1mL and more. The currest status of Spascupreel drug is Active.

Drug Information:

Drug NDC: 50114-7040
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Spascupreel
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Aconitum Napellus, Ammonium Bromide, Citrullus Colocynthis Fruit Pulp, Atropine Sulfate, Gelsemium Sempervirens Root, Magnesium Phosphate, Dibasic Trihydrate, Veratrum Album Root, Passiflora Incarnata Flowering Top, Matricaria Recutita, Amanita Muscaria Fruiting Body And Cupric Sulfate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Medinatura Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACONITUM NAPELLUS - 6 [hp_X]/1.1mL
AMANITA MUSCARIA FRUITING BODY - 4 [hp_X]/1.1mL
AMMONIUM BROMIDE - 4 [hp_X]/1.1mL
ATROPINE SULFATE - 6 [hp_X]/1.1mL
CITRULLUS COLOCYNTHIS FRUIT PULP - 4 [hp_X]/1.1mL
CUPRIC SULFATE - 6 [hp_X]/1.1mL
GELSEMIUM SEMPERVIRENS ROOT - 6 [hp_X]/1.1mL
MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE - 6 [hp_X]/1.1mL
MATRICARIA RECUTITA - 3 [hp_X]/1.1mL
PASSIFLORA INCARNATA FLOWERING TOP - 2 [hp_X]/1.1mL
VERATRUM ALBUM ROOT - 6 [hp_X]/1.1mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRADERMAL
INTRAMUSCULAR
INTRAVENOUS
SUBCUTANEOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 30 Aug, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 30 Nov, 2023
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 25 Dec, 2025
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:MediNatura Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:U0NQ8555JD
DIF093I037
R0JB3224WS
03J5ZE7KA5
23H32AOH17
LRX7AJ16DT
639KR60Q1Q
HF539G9L3Q
G0R4UBI2ZZ
CLF5YFS11O
QNS6W5US1Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Anticholinergic [EPC]
Calculi Dissolution Agent [EPC]
Cholinergic Antagonists [MoA]
Cholinergic Muscarinic Antagonist [EPC]
Cholinergic Muscarinic Antagonists [MoA]
Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]
Magnesium Ion Exchange Activity [MoA]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
50114-7040-110 AMPULE in 1 CARTON (50114-7040-1) / 1.1 mL in 1 AMPULE30 Aug, 201430 Nov, 2023No
50114-7040-21 AMPULE in 1 CARTON (50114-7040-2) / 1.1 mL in 1 AMPULE30 Aug, 201430 Nov, 2023No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Spascupreel aconitum napellus, ammonium bromide, citrullus colocynthis fruit pulp, atropine sulfate, gelsemium sempervirens root, magnesium phosphate, dibasic trihydrate, veratrum album root, passiflora incarnata flowering top, matricaria recutita, amanita muscaria fruiting body and cupric sulfate aconitum napellus aconitum napellus ammonium bromide bromide ion citrullus colocynthis fruit pulp citrullus colocynthis fruit pulp atropine sulfate atropine gelsemium sempervirens root gelsemium sempervirens root magnesium phosphate, dibasic trihydrate magnesium cation veratrum album root veratrum album root passiflora incarnata flowering top passiflora incarnata flowering top matricaria recutita matricaria recutita amanita muscaria fruiting body amanita muscaria fruiting body cupric sulfate cupric cation sodium chloride water

Indications and Usage:

Indication and usage spascupreel® injection solution is a homeopathic drug product indicated for the relief of spasms of the smooth musculature of the gastrointestinal and the urogenital tract as well as general muscle spasms.

Warnings and Cautions:

Warnings and precautions keep out of reach of children.

Dosage and Administration:

Dosage and administration general considerations the dosage schedules listed below can be used as a general guide for the administration of spascupreel® injection solution. spascupreel® injection solution may be administered s.c., i.d., i.m., or i.v. if co-administration with a local anesthetic is desired, spascupreel ® injection solution may be mixed with lidocaine or similar agents at the discretion of the physician. the interval between injections is left to the discretion of the hcp, but should not exceed 1 ampule in 24 hours. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. discard any unused ampule contents. draw up required dose into syringe. discard any unused ampule contents. do not reuse ampule. only licensed practitioners with sufficient expertise in injecting drugs, including the respective route of administration, should administer the product. standard d
osage: adults and children 12 years and older: 1 ml 1 to 3 times per 7 days. children 6 to 11 years: 0.7 ml 1 to 3 times per 7 days. children 2 to 5 years: 0.5 ml 1 to 3 times per 7 days. acute dosage: adults and children 12 years and older: 1 ml daily, and then continue with standard dosage. children 6 to 11 years: 0.7 ml daily, and then continue with standard dosage. children 2 to 5 years: 0.5 ml daily, and then continue with standard dosage.

Dosage Forms and Strength:

Dosage 1 ampule containing 1.1 ml solution for injection.

Contraindications:

Contraindications spascupreel ® injection solution is contraindicated in patients with known hypersensitivity to spascupreel ® or any of its ingredients.

Adverse Reactions:

Adverse reactions post-marketing experience no adverse events have been reported with a causal relationship to spascupreel® injection solution. to report suspected adverse reactions, contact medinatura. at 1.844.633.4628 or info@medinatura.com or fda at 1-800-fda-1088 or www.fda.gov/medwatch .

Description:

Description each 1.1 ml solution for injection ampule contains: active ingredients: ingredient name potency quantity final dilution aconitum napellus 6x 2.20 µl 8.69x agaricus muscarius 4x 0.55 µl 7.30x ammonium bromatum 4x 1.10 µl 7.00x atropinum sulphuricum 6x 1.10 µl 8.99x chamomilla 3x 0.55 µl 6.30x colocynthis 4x 1.10 µl 7.00x cuprum sulphuricum 6x 0.55 µl 9.30x gelsemium sempervirens 6x 1.10 µl 8.99x magnesia phosphorica 6x 1.10 µl 8.99x passiflora incarnata 2x 0.55 µl 5.30x veratrum album 6x 1.10 µl 8.99x inactive ingredients: water for injection 1,089.0 μl sodium chloride 10.4 μl

Clinical Pharmacology:

Clinical pharmacology mechanism of action the exact mechanism of spascupreel® injection solution is not fully understood. pharmacodynamics not applicable for homeopathic medicinal products.

Package Label Principal Display Panel:

Spascupreel 1.1ml injection.jpg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.